FDA approves Aduhelm, first new Alzheimer’s disease treatment since 2003


Sumary of FDA approves Aduhelm, first new Alzheimer’s disease treatment since 2003:

  • The FDA today granted accelerated approval for Aduhelm, the first new treatment to be approved for Alzheimer disease since 2003..
  • “As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research and innovation.”.
  • The most common side effects associated with Aduhelm involved ARIA, headache, fall, diarrhea and confusion/delirium/altered mental status/disorientation..
  • Late last year, the FDA Peripheral and Central Nervous System Drugs Advisory Committee met to discuss a Biologics License Application for Aduhelm..
  • Under the accelerated approval, the FDA is requiring Biogen to perform a new randomized controlled trial to verify the drug clinical benefit..
  • If that new trial fails to verify clinical benefit, the FDA “may initiate proceedings to withdraw approval of the drug,”…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.